Share
4,552 Posts.
lightbulb Created with Sketch. 509
clock Created with Sketch. 06/12/24
20:52
Share
Originally posted by stzenit:
↑
I think everyone here does expect a cap raise at some point in the new year. Would have just under $10mil right now. The conference should generate a lot of interest and depending on how robust the P2 Data is we would want to have a good cash position going into any future negotiations regarding buyout. I don't think pharma will throw down big coin until a larger cohort gets stress tested so most likely path is cap raise and a licensing deal at some point following the conference. We are still significantly undervalued though, especially when you do a market cap peer comparison and then throw in the potential buyout figures. Very early if this plays out how we all hope it does.
Expand
Thank you stzenit for an articulate and well written answer.
